Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Innovator McKinley Income Fund Class Investor Shares (IMIFX)

Net Asset Value
1 Day
Overall Morningstar Rating
Aggressive allocation
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks current income and, as a secondary objective, long-term capital appreciation. Under normal circumstances, the fund seeks to achieve its objective by investing in a portfolio of U.S.-listed, exchange-traded stocks and bonds, as well as other mutual funds and business development companies ("BDCs"), that the portfolio manager believes offers high current income. These securities may include "pass-through" securities (structured to pass through a majority of income as distributions to shareholders) such as master limited partnerships, royalty trusts, and real estate investment trusts.


1 month-5.67% 3 years-6.50%
3 months-15.25% 5 years--
1 year-22.30% Since inception-1.68%
Data through --

Peer Comparisonvs. Aggressive allocation

Performance 5-yr return--+6.69%
Expense ratio2.59%1.36%
Risk 5 year sharpe ratio--0.53
Net assets$23.3M$902.8M
Average market cap$6.8B$35.1B
Average P/E16.917.8
Portfolio turnover73%73%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyInnovator Funds
Fund manager & tenureRobert Gillam / 0 Years
Minimal initial investment$2,000.00
Minimum IRA investment--


U.S. stock87.73%
International stock10.20%
Fixed income0.00%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
PSEC Prospect Capital Corp4.13%
VGR Vector Group Ltd3.70%
CLMT Calumet Specialty Products Partners LP3.35%
RAI Reynolds American3.12%
NEWM New Media Investment Group Inc3.10%
BX Blackstone Group3.09%
MO Altria Group3.06%
AB AllianceBernstein Holding LP3.02%
KKR KKR & Co LP2.87%
AZN AstraZeneca2.85%

Partner Offers